Jubilant Ingrevia Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Specialty & CDMO drive a 29% EBITDA jump: Specialty Chemicals grew 11% YoY with 27% margins, while the CDMO pharma funnel doubled and the first agro CDMO delivery shipped.
• Nutrition is the drag, but the fix is visible: Niacinamide prices and lean customer inventories pushed the segment down 4% YoY; the new cosmetic-grade cGMP facility is ramping up and EU anti-dumping duties on Chinese Choline promise a tailwind.
• Chemical Intermediates found a floor: Acetic Anhydride volumes recovered on agrochemical demand, lifting segment EBITDA 63% QoQ, though pricing remains muted.
• The cost lever is deliberate and quantified: Lean 2.0 targets ₹100+ crore in annualised savings for FY26, with progress already booked in Q1.
• What to watch next quarter: Whether Niacinamide offtake normalises, the pace of the EU Choline opportunity converting to orders, and margin expansion in Chemical Intermediates as input costs ease.

Specialty Chemicals & CDMO: The Growth Engine

• Fine Chemicals and CDMO led the quarter: Segment revenue grew 11% YoY, with margins holding at an elevated 27% driven by high-margin orders, steady Pyridine and Diketene pricing, and continuous cost optimisation.
• CDMO pharma pipeline doubled: The opportunity funnel expanded significantly in a few months, driven by strong traction from innovative pharma companies and Tier-1 CDMOs across the EU, US, and Japan.
• Agro CDMO moved from promise to delivery: The first key agro CDMO order was shipped with a 'First Time Right' approach in Q1 FY26 after plant modifications were completed. Capex for the second, larger \$300 million agro contract is on track for early 2026 supply.
• Semiconductor foray is early but resourced: A dedicated team is in place, R&D investments have been made, and over 12 opportunities sit in the funnel, though no revenue timeline is given.
• Capacity is being stretched proactively: Debottlenecking and expansion initiatives are underway for Diketene derivatives and core Pyridine platforms to unlock additional capacity for new products.

Deepak Jain: "In our CDMO business, the pharmaceutical segment saw a significant expansion in its opportunity pipeline, with the funnel doubling in size in last few months."

Nutrition & Health Solutions: The Near-Term Drag

• Niacinamide prices and destocking hurt: Revenue declined 4% YoY and 6% QoQ as customers delayed purchases and maintained lean inventories amid competitive offerings. EBITDA margin compressed to 14% from 16% QoQ, driven by lower Niacinamide volumes and prices.
• Cosmetic-grade is the bright spot: Demand surged on both a QoQ and YoY basis, and the new cGMP facility for cosmetic-grade B3 is receiving an exceptional response, with improving realisations as the mix shifts.
• Choline demand rose notably: Prices held steady while volumes grew both YoY and QoQ, sustaining Jubilant's #1 position in the domestic Dry Choline Chloride market.
• EU anti-dumping duty is a tangible tailwind: The duty on Chinese Choline Chloride is expected to strengthen Jubilant's competitive edge, and the company is already in touch with multiple EU customers for sales.
• Human Nutrition is being built out: A dedicated team is in place, 2-3 more human-grade products are in the pipeline, and pre-mixes are in the process of launching, with Choline Chloride and Choline Bitartrate as anchor products.

Chemical Intermediates: Early Recovery

• Acetic Anhydride volumes recovered sequentially: The uptick was driven by a marginal recovery in demand from the agrochemical sector, helping segment revenue improve 2% QoQ.
• EBITDA jumped 63% QoQ: The improvement was supported by higher Acetic Anhydride volumes and a slight reduction in Acetic Acid input costs, though overall pricing in the segment stayed muted.
• Ethyl Acetate is a strategic volume push: Volumes grew YoY as part of a deliberate emphasis, even as prices remained at the lower end of the spectrum.
• Margin expansion is promised, not dated: Management expects margins to expand in a few quarters through ongoing cost optimisation and easing freight rates, making this a recovery to track rather than bank.

Cost & Margin Levers

• Lean 2.0 is the quantified margin story: The programme targets annualised savings exceeding ₹100 crore in FY26 and has already progressed well in Q1, enhancing profitability alongside lower raw material costs.
• Specialty margins are structurally elevated: At 27%, the segment benefits from a mix shift toward high-margin orders within the Specialty portfolio, steady pricing in select derivatives, and continuous cost optimisation.
• Nutrition margin compression is price-driven: The 200 bps QoQ drop to 14% is tied to Niacinamide, making a recovery contingent on offtake normalising and cosmetic-grade mix improving.
• Generative AI is being deployed in R&D: Integration has begun to accelerate pipeline development and enhance agility in product innovation, though no financial impact is quantified.

Strategic Positioning & Market Context

• The portfolio is now 63% of revenue and 90% of EBITDA: Specialty Chemicals and Nutrition together dominate the profit pool, underscoring the strategic weight of the Pinnacle strategy.
• China+1 is creating a healthy funnel: The macro-trend is generating more opportunities, especially in Specialty Chemicals, with supply chain diversification driving traction across Pharma, Agro, and Semiconductor segments.
• Pyridine and Beta-Picoline leadership is defended: Jubilant remains the only scaled non-Chinese player with a global #1 position, and QoQ volume growth drove overall sales despite some short-term price volatility.
• EU volumes saw a short-term dip: Reduced offtake across Specialty Chemicals and Nutrition impacted the region, though the EU anti-dumping duty on Choline is expected to reverse some of this.
• The global chemicals cycle is turning slowly: The sector is emerging from inventory destocking, with Specialty Chemicals seeing volume growth but stable pricing, while commodity segments still face demand challenges with prices stabilising at lower levels.

Shyam S Bhartia & Hari S Bhartia: "We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis."

Guidance & Commitments

Key Metrics